SLG
CPIX icon

Stanley-Laman Group’s Cumberland Pharmaceuticals CPIX Stock Holding History

Stanley-Laman Group’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-35,078
Closed -$158K – 270
2016
Q1 		$158K Sell
35,078
-45,257
-56% -$216K 0.03% 270
2015
Q4 		$423K Sell
80,335
-3,149
-4% -$17.9K 0.07% 243
2015
Q3 		$482K Buy
+83,484
New +$520K 0.1% 202

Other funds holding CPIX

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Stanley-Laman Group's CPIX Position: Q2 2016 in Review

Stanley-Laman Group sold out of Cumberland Pharmaceuticals (CPIX) in Q2 2016, closing a stake of 35,078 shares — an estimated $158K sold.

Stanley-Laman Group first reported a position in CPIX in Q3 2015 and held it in 3 quarters. The position peaked at $482K in Q3 2015. 44 funds tracked by Wall St. Rank hold CPIX as of Q2 2016.

  • Stanley-Laman Group reported no remaining Cumberland Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Stanley-Laman Group sold 35,078 Cumberland Pharmaceuticals shares in Q2 2016, an estimated $158K.
  • Stanley-Laman Group first reported a position in Cumberland Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • Stanley-Laman Group's Cumberland Pharmaceuticals position peaked at $482K in Q3 2015.
  • 44 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2016.

Based on Stanley-Laman Group's 13F filing for Q2 2016, filed 4 Aug 2016.